Clinical Trials Browser

omburtamab I-131 × Clear all

Ependymoma, Medulloblastoma

NCT05064306 2025-08-01

131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults

CNSGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Medulloblastoma, Meningeal Neoplasms, Wilms Tumor, Neuroblastoma, Pinealoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT03275402 2024-02-13

131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Phase 2/3 Terminated

52 enrolled 11 charts

CNS

Neuroblastoma, Meningeal Carcinomatosis

NCT00089245 2023-12-26

Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer

Phase 1 Terminated

177 enrolled

CNSSarcoma

Brain Neoplasms, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Meningeal Carcinomatosis, Desmoplastic Small Round Cell Tumor

Clinical Trials

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults

131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer